Chemotherapy-induced Nausea and Vomiting Drugs

Global Market Trajectory & Analytics

MCP11004

EXECUTIVE ENGAGEMENTS

OUTREACH

3309
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

596
Interactions with Platform & by Email

PARTICIPANTS

99
Unique # Participated

VALIDATIONS

46
Responses Validated*

COMPETITORS

41
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

63

PAGES

134

EDITION

8

PRICE

USD $4950


  

HIGHLIGHTS

Amid the COVID-19 crisis, the global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurokinin NK1 Receptor Antagonist segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$667.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$565.6 Million by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
In the global Dopamine Antagonist segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$294.1 Million in the year 2020 will reach a projected size of US$409.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368.2 Million by the year 2027.

SELECT PLAYERS

Acacia Pharma Group Plc; Aphios Corporation; Baxter International Inc.; Dr. Reddy's Laboratories Ltd.; Eisai Co., Ltd.; Especificos Stendhal S.A. DE C.V.; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Helsinn Healthcare SA; Heron Therapeutics, Inc.; Kyowa Hakko Kirin Co., Ltd.; Lee's Pharmaceutical Holdings Ltd.; Merck & Co., Inc.; Midatech Pharma PLC; Mundipharma Pte., Ltd.; Mylan N.V.; Ono Pharmaceutical Co., Ltd.; Opko Health, Inc.; Orchid Chemicals & Pharmaceuticals Ltd; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma LP; Sandoz International GmbH; SciClone Pharmaceuticals, Inc.; Shin Nippon Biomedical Laboratories Ltd. (SNBL); Solasia Pharma K.K.; Specialised Therapeutics Asia Pte Ltd; Sun Pharmaceutical Industries Ltd.; Taiho Pharmaceutical Co., Ltd.; Tesaro, Inc.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Segment (Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine, Other Segments)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
Total Companies Profiled: 41

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com